Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. SCYNEXIS
SCYX

Buy SCYNEXIS (SCYX) Stock

SCYX
See SCYX stock price and Buy/Sell SCYNEXIS with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
SCYX

SCYNEXIS (SCYX)

About SCYNEXIS (SCYX)

SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monn...Read more
Market Cap
$68.42M
1 Year High
$10.25
Volume
1 Year Low
$1.81
Price to Earnings Ratio
Open
$2.09
Dividend Rate
High
$2.19
Dividend Yield
Low
$2.06

Community

People who own or watch SCYX stock

SCYNEXIS Stock News

SCYNEXIS stock rating

What analysts recommend for SCYX stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
1

SCYNEXIS price target

What analysts think SCYX will be worth
Low $1.81
High $24.08
Current $2.10
Target $24.08

Events

List of events that could affect SCYX stock.
12May

Earnings data Q1 2022

15Aug

Earnings data Q2 2022

SCYNEXIS earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.35
-0.7
-1.05
Q3 2021
Q4 2021
Q1 2022
Q2 2022

Expected EPS
Q2 2022
-$0.54
Actual EPS
Q2 2022

Buy SCYNEXIS (SCYX) Stock

SCYX
See SCYX stock price and Buy/Sell SCYNEXIS with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch SCYX stock
  • sherwin51 avatar
  • Johnrok avatar
  • chrisismath avatar
  • normanj avatar
  • ricofly3 avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.